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We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib
therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also
measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below
the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient
recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in
patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy
may result in leptin alteration.
& 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Chronic myelogenous leukemia (CML), a rare disease in
children and young people, is a myeloproliferative neoplasm
consistently associated with the BCR-ABL fusion gene. The onco-
protein BCR-ABL, deranges the balance of cell growth and death in
normal hematopoietic cells. The BCR-ABL tyrosine kinase (TK)
inhibitor, imatinib mesylate (IM), is an effective treatment for
CML. Although IM inhibits TKs associated with speciﬁc diseases,
in vivo inhibition of PDGF receptor and c-kit may also occur and
may have clinical consequences. IM is well tolerated and mole-
cular remission can be achieved in children and adults. However,
altered bone and mineral metabolism [1,2] and severe oligozoos-
permia [3] in patients taking IM before puberty, and reduction of
testosterone and gynecomastia [4], thyreopathy [5] and other
endocrinological disorders in a proportion of adult patients has
been reported [6].
Leptin, synthesized in adipocytes, is a regulator of fat metabo-
lism and reproduction [7]. The levels of leptin correlate with body
fat mass and show a wide variation in individuals. In the bone
marrow microenvironment, the leptin secreting adipocytes occupy
a signiﬁcant part [8]. Leptin stimulates hematopoietic stem cellsr Ltd.
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cell lineage, and is involved in the growth of hematopoietic
malignancies [9]. An increase of leptin in IM treated CML adult
patients in molecular remission has recently been observed [10].
Here we evaluated the serum leptin concentrations in young CML
patients during IM assumption. Our data indicate that, regardless
of BMI and percentage of fat mass (FM), long term IM treatment
may induce modiﬁcation of leptin secretion.2. Subjects and methods
2.1. Patients
Nine patients with CML, under IM, referred to our center for
an endocrinological workup, were studied (5 male and 4 female;
mean age 17.0675.5 years). Weight and height were measured
and the body mass index (BMI) was calculated as weight in kg
divided by the square of height in meters. Follow-up included
physical examination, complete blood counts, leptin serum levels
and FM% determination. IM was administered orally 400 mg daily.
Cytogenetic and molecular responses were assessed periodically.
Complete cytogenetic, hematological, and molecular remission
(MMolR, BCR-ABL/ABL o0.05%) was attained and persisted during
follow-up, except for a male patient (case 2) who stopped IM after
3.4 years because of a cytogenetic relapse, and underwent stem
cell transplantation (SCT). During the study 3 patients (cases 1,
5 and 6) in major molecular response were scheduled to receive an
intermittent therapy, consisting in 400 mg daily of IM taken three license.
Table 1
Leptin levels, BMI and fat mass during follow-up.
Cases Sex Age (yr) IM administration Months on IM Leptin
(ng/ml)a
BMI (kg/m2) FM (%)
1 M 14.0 daily 29 7.9 19.23 17.6
16.6 daily 59 7.8 18.51 n.a.
17.6 b 71 2.0 18.50 15.6
18.5 b 82 2.1 n.a. n.a.
2 M 11.3 daily 27 8.5 21.62 n.a.
12.6 daily 42 16.8 22.5 29.4
13.2 c — 5.6 18.75 n.a.
3 M 14.8 daily 15 8.5 n.a. n.a.
17.9 daily 52 10.1 24.26 22.8
19.7 daily 74 10.6 22.51 19.3
4 M 22.2 daily 26 39.4 24.0 n.a.
22.8 daily 32 44.3 n.a. n.a.
23.2 daily 38 33.5 24.0 12.4
5 M 15.10 daily 46 o1 18.57 9.2
16.5 daily 53 1.2 20 n.a.
17.4 daily 64 2.2 n.a. 10.7
18.3 b 75 2.1 21.42 11.3
19.3 b 87 2.0 20.52 n.a.
6 F 14.0 daily 48 39.9 19.36 27.4
15.0 b 60 15.6 19.11 n.a.
15.11 b 71 19.3 19.62 32.0
16.10 b 82 20 19.10 32.4
7 F 29.4 daily 6 14.1 23.40 n.a
31.5 daily 31 13.5 n.a. 34.1
33.0 daily 50 14.7 24.11 33.7
8 F 14.4 daily 1 32.2 21.48 n.a.
15.0 daily 9 24.1 n.a. n.a.
16.3 daily 24 24.1 22.9 41.0
9 F 18.4 daily 49 15.7 n.a. n.a.
19.2 daily 59 13.0 19.85 23.8
20.11 daily 80 13.7 19.48 23.8
IM: imatinib
a normal leptin values: for males 2.0–5.6 ng/ml; for females 3.6–11.1 ng/ml; n.a.: not available
b Start of intermittent treatment with IM (3 weeks on and 1 week off per month)
c IM discontinuation; FM: body fat mass.
S. Mariani et al. / Leukemia Research Reports 2 (2013) 58–60 59weeks on and one week off every month. This study was
conducted in accordance with the Declaration of Helsinki and
was approved by the Institutional Ethics Committee.
2.2. Leptin assay
Leptin concentrations were measured using an ELISA kit
(human leptin ELISA, Millipore, St. Charles, Mo., USA). The intra-
and inter-assay coefﬁcient of variation was 2.6–4.6% and 2.6–6.2%,
respectively. Serum leptin concentration was expressed in ng/ml.
2.3. FM evaluation
FM was measured by dual energy X-ray absorptiometry (DEXA)
(Hologic Inc., Bedford, MA, USA, QDR 4500W, S/N 47168) by one
single experienced technician. Speciﬁc delimiters for regional
analysis were determined by a standard software (Hologic Inc.,
QDR 4500W S/N 47168 VER. 11.2). Total body fat mass was
expressed in percentage.3. Results
Table 1 shows the demographic, anthropometric, serum leptin
and FM characteristics of the patients during follow-up.
Leptin concentrations were outside the reference values in all
patients. In particular, leptin was higher than normal in 8 patientsand lower in one (case 5). All the subjects were within the normal
BMI range (18.5–24.26 kg/m2). The FM% was higher than normal in
3 cases. However, on the whole, no apparent relationship
was found between the FM% and leptin levels. The patient who
interrupted IM after 3.4 years of assumption (case 2) recovered the
leptin normal value after drug discontinuation. The three patients
who started the IM intermittent treatment (cases 1, 5, and 6),
showed a trend toward an improvement of leptin values.4. Discussion
We determined whether the long-term IM therapy induces
leptin modiﬁcation in young patients treated for CML.
Among the patients under IM in our series, 8 out of 9 had levels
of leptin higher than the highest reference range while in one
it was lower. In agreement with the reported lack of association
between anthropometric measures, including BMI, and CML, [11]
all our patients had a normal BMI, indicating that the variation of
leptin was not ascribable to an excess of body weight. However,
being BMI an inaccurate measure of fatness, we measured the FM%
by DEXA. 3 subjects had a FM% higher than normal. In these cases,
we cannot rule out an inﬂuence of FM excess on leptin values.
In the remaining patients, the FM% was within the normal range,
suggesting that the modiﬁcation of leptin may be associated with
IM use. As a matter of fact, the highest leptin concentration was
measured in a patient with FM% in the lower normal limit.
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that, under IM, all CML patients in molecular remission had a
signiﬁcant increase in leptin compared to baseline. A possible
causal relationship between IM intake and leptin modiﬁcation is
further reinforced by the results obtained here after IM with-
drawal. Infact, one patient who stopped IM and underwent SCT,
recovered the leptin normal value. Furthermore, three patients
showed a trend toward a normalization of leptin when scheduled
to intermittent IM therapy.
An interaction between IM and leptin is made plausible by the
sharing of some intracellular signaling pathways and by the
interplay with common hematopoietic growth factors. Note-
worthy, IM modulates the activity of MEK/MAPK, STAT and other
intracellular signals [12] and leptin regulates, and is reciprocally
regulated, by the same pathways[13]. Moreover, previous clinical
data showed that IM may cause long-term endocrine and meta-
bolic side-effects [1–6]. The receptor for leptin is expressed in
hematopoietic stem/progenitor cells. In bone marrow, leptin is
secreted from local adipocytes, which occupy most of the marrow
cavity in humans, and stimulates myeloid and erythroid develop-
ment. Therefore, leptin and leptin receptors might play an impor-
tant role in the control of the expansion and differentiation
of primitive hematopoietic cells through paracrine interaction in
the bone marrow [8,14,15]. The fat cell content of the bone
marrow may thus reﬂect the requirement for leptin in hematopoi-
etic development. Leptin receptors are also expressed in leukemic
cells from patients affected by CML, acute myeloblastic leukemia
and acute lymphoblastic leukemia. Particularly, in CML higher
expression of leptin receptors has been observed during blast
crisis than in the chronic phase [16]. Moreover, leptin alone and in
combination with other cytokines, shows anti-apoptotic and pro-
liferative effects on leukemia cells, suggesting that leptin may play
an active role in the pathophysiology of leukemia [16]. All
together, these data reinforce the view that IM may inﬂuence
either directly or indirectly leptin.
This study has some limitations. First, the sample size allows
only a partial conclusion, although patients were monitored for a
long period and CML is a rare disease in young people. The lack of
leptin measurements before IM is a further limitation, although
the out of range values found during the follow-up could be an
attracting starting point for future research. Finally, the time
intervals in the monitoring of the patients were irregular.
In conclusion, the knowledge of the side effects of TKs inhibi-
tors is increasing. Nonetheless, the patients chronically exposed to
targeted therapies need investigations on long-term side effects of
these drugs. The identiﬁcation of speciﬁc hormonal proﬁles that
correlate with tumor progression or with the success of the
therapy may represent an important step in evaluating potential
target therapy. These data will contribute to a better understand-
ing of the mechanism of TK inhibitors action and of their safety
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